PHARMACEUTICAL MARKET RESEARCH REPORTS

Industry Standard Research – ISR Reports – is a full-service pharmaceutical market research company operating exclusively in the life sciences industry and a sister company of Outsourced Pharma. Their syndicated and custom market research capabilities enable their customers to make smarter, more informed business decisions. You’ll find links to their pharmaceutical market syndicated research reports below.

ISR's market research reports are produced using direct feedback from decision-makers, which enables ISR to provide data on topics that, until now, were only attainable through custom research. With rigorous screening criteria and methodologies that include surveys, in-depth phone interviews, and focus groups, ISR gathers actionable information that is immediately applicable to their customers. Each report is available to purchase online and you may also download free preview files. If you have any questions, please feel free to email info@ISRreports.com.

TRENDS AND MARKET OUTLOOK REPORTS

  • Emerging Biopharma Perspective On Highly Potent API Manufacturing Market
    Emerging Biopharma Perspective On Highly Potent API Manufacturing Market

    An overview of the current market dynamics for high containment manufacturing from the perspective of HPAPI manufacturing decision-makers at sponsor organizations at small and midsize biopharmaceutical companies and their predictions on what the market will look like in five years.

  • Highly Potent API Market Outlook
    Highly Potent API Market Outlook

    This report provides an overview of the current market dynamics for high containment manufacturing as well as an outlook on what some HPAPI manufacturing decision-makers at sponsor organizations predict the marketplace will look like five years from now.

  • Cell & Gene Therapies Market Outlook
    Cell & Gene Therapies Market Outlook

    Outsourcing decision-makers for cell or gene therapies at sponsor organizations give an overview of the current market dynamics in the cell & gene therapies contract manufacturing space and predictions through 2026.

  • Sterile Injectable Drug Product Manufacturing Market Outlook (3rd Ed.)
    Sterile Injectable Drug Product Manufacturing Market Outlook (3rd Ed.)

    This report explores which delivery formats drug innovators are using in their pipelines and portfolios, how likely innovators are to outsource manufacturing based on delivery device, and how these proportions will shift over the next five years.

  • Oral Dosage Forms Market Overview and Outlook (4th Edition)
    Oral Dosage Forms Market Overview and Outlook (4th Edition)

    This market research report provides an overview of the current market dynamics in the oral dose contract manufacturing space as well as an outlook of what our survey respondents—all oral dose outsourcing decision-makers at sponsor organizations—predict the marketplace will look like in 2024. Key statistics include oral dose project volume, percentage outsourced, and the average number of CMOs used to...

  • Clinical Manufacturing Market Dynamics and Service Provider Benchmarking
    Clinical Manufacturing Market Dynamics and Service Provider Benchmarking

    This report provides an overview of the current market dynamics in the clinical manufacturing space as well as an outlook of what our survey respondents predict the marketplace will look like in 2022.

  • Bioprocessing Market Trends and Outsourcing Dynamics: 2020-2025 (3rd Edition)

    This market research report affords readers the opportunity to gain insight into the bioprocessing market and where it’s heading. This report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what our survey respondents predict the marketplace will look like in five years.

  • Pharmaceutical Excipient Market Overview and Outlook
    Pharmaceutical Excipient Market Overview and Outlook

    This market research report offers readers the opportunity to gain insight into the biopharmaceutical excipient market and where it’s heading. Remaining aware of market dynamics and expected changes will enable readers to better make key decisions regarding excipient use and to help identify where competitive advantages may be gained.

  • Development vs. Commercial Outsourced Manufacturing Practices: Small Molecule
    Development vs. Commercial Outsourced Manufacturing Practices: Small Molecule

    This report explores how the decision-making process differs among drug innovators outsourcing development activities from those outsourcing commercial manufacturing when it comes to CMO/CDMO selection criteria, use patterns, preferences and perceived leadership.

  • Development vs Commercial Outsourced Manufacturing Practices: Biologics
    Development vs Commercial Outsourced Manufacturing Practices: Biologics

    This market research report explores how the decision-making process differs among drug innovators outsourcing development activities from those outsourcing commercial manufacturing when it comes to CMO/CDMO selection criteria, use patterns, preferences and perceived leadership.

Interested In Custom Research?

CONTRACT MANUFACTURER QUALITY BENCHMARKING

  • Biologic API CDMO Benchmarking (7th Ed.)
    Biologic API CDMO Benchmarking (7th Ed.)

    This report offers a comprehensive analysis of current outsourcing trends and practices, in addition to a quantitative analysis of CMO service quality across a series of 22 performance attributes.

  • Biologic Drug Product CDMO Benchmarking (5th Ed.)
    Biologic Drug Product CDMO Benchmarking (5th Ed.)

    This report provides pharmaceutical companies and contract manufacturers a comprehensive analysis of current outsourcing trends and practices, in addition to a quantitative analysis of CMO service quality.

  • Small Molecule Drug Product CDMO Benchmarking (5th Ed.)
    Small Molecule Drug Product CDMO Benchmarking (5th Ed.)

    This report has been designed to help biopharmaceutical companies make more informed CMO decisions, and to help CMOs optimize operational and marketing strategies.

  • Biologic API CDMO Benchmarking For New & Emerging Pharma
    Biologic API CDMO Benchmarking For New & Emerging Pharma

    This report is based on responses from 45 people involved in outsourced large molecule API projects over the last 18 months. It will help new/emerging pharma companies make informed CDMO selections, and help CDMOs better understand how they are perceived.

  • Small Molecule API Contract Manufacturer Quality Benchmarking (6th Edition)
    Small Molecule API Contract Manufacturer Quality Benchmarking (6th Edition)

    This report includes data on 358 service encounters from 123 respondents who have been involved in outsourced small molecule API projects in the past 18 months. It will help biopharma companies make more informed CMO decisions, and help CMOs optimize operational and marketing strategies.

Interested In Custom Research?

DEPARTMENT MODELS AND STRUCTURES

  • CDMO Outsourcing Models (4th Ed.)
    CDMO Outsourcing Models (4th Ed.)

    This market research report explores how sponsor organizations use contract manufacturers to streamline costs, better manage capacity, access scientific expertise, improve efficiencies and decrease time to market.

  • Benchmarking the Pharma Industry's Market Research Function
    Benchmarking the Pharma Industry’s Market Research Function

    ISR conducted five in-depth interviews and 31 online surveys with experienced market researchers in the biopharmaceutical space to gain a better grasp on the market research function. Research subjects shared their insights on the types of research performed, how their market research function is structured, and outsourcing behavior.

  • The CMC Function: Best Practices and Optimization
    The CMC Function: Best Practices and Optimization

    ISR interviewed 15 CMC professionals at 14 Top 50 pharmaceutical and biotechnology companies, as well as one company outside the Top 50 to better understand the Chemistry Manufacturing and Controls function throughout the preclinical, clinical, and commercialization phases of the product development process.

  • Benchmarking The Pharma Industry's Medical Science Liaison (MSL) Function
    Benchmarking The Pharma Industry’s Medical Science Liaison (MSL) Function

    This market research report has been designed to be used as a benchmarking tool for companies to compare their Medical Science Liaison functions to those of other pharmaceutical and biotech organizations. You can purchase a single-user license for individual use, a site-wide license giving access to the report for all employees within...

Interested In Custom Research?

ISR ARTICLES

  • Five Steps To CDMO Selection

    Sponsors will see success in their CDMO partnerships by dedicating time and effort to establish a plan that identifies outsourcing drivers, to select a model that matches company needs and resources, to establish a decision-making process and group, and to designate key selection criteria. Using these steps, drug developers can build strategic outsourcing relationships where their internal expertise is complemented by external CDMO resources.

  • Where Bioprocessing Outsourcers Stand On Capacity Concerns

    Insights into bioprocessing outsourcers’ level of concern regarding current and upcoming available capacity, whether they are currently facing limits, and what they plan to do about a potential shortage.

  • Industry Trends: CDMO Outsourcing

    No single CDMO strategy or outsourcing model is appropriate for every project. Outsourcers can and should evaluate a strategy and partner(s) on a case-by-case basis.

  • Small Molecule Drug Substance Outsourcing Drivers

    ISR asked 57 respondents who outsource small molecule API which reason fits best with their company’s capacity for, and experience with, manufacturing small molecule drug substance. Read how the data shows the most common reason for outsourcing API manufacturing is a lack of capacity despite possessing in-house experience (42%).

     
  • Biologic Drug Substance Outsourcing Drivers

    ISR data from Q2 2022 shows the most common reason for outsourcing bioprocessing is a lack of capacity despite possessing in-house experience (41%).

ABOUT ISR VIDEO

WHY ISR?

ISR understands that you’re looking for confidence in your market research. With ISR, you’ll consistently receive:

  • Focused Domain Expertise — We’ve operated in pharmaceuticals for over 15 years and because it’s our sole focus, our domain expertise brings value to the work that “generalist” researchers can’t deliver.
  • Genuine Research Expertise — Our market research experience has developed over 20 years in many dynamic industries.  We capture appropriate sample sizes, given the research objectives, and we use appropriately sophisticated statistics to uncover everything that’s real and to give you confidence in your decisions. Read our Six Questions to Ask About Your Market Research to learn more about why our industry expertise sets us apart.
  • Transparency — If you’re like many, you’ve been disappointed more than once by research providers who fail to live up to their promises, providing you with their “professional judgment” in place of sound data; and suspect contacts instead of real decision-makers. We deliver the beliefs, attitudes, and intentions of people who matter – and we’ll prove it by showing you the titles of your respondents.

For additional questions about any of ISR’s reports or custom research services, please contact us at info@ISRreports.com.